Drug intelligence / Profile preview

SQZ-APC-KRAS

Development stage: Preclinical
Lead developer: SQZ Biotechnologies
Modality: Cell Therapies

Overview

SQZ-APC-KRAS is an autologous antigen-presenting cell therapy developed by SQZ Biotechnologies using its Cell Squeeze platform to load patient-derived cells with mutant **KRAS G12D** and **KRAS G12V** peptides. The product is designed to stimulate mutation-specific CD8+ T-cell responses against tumors harboring these oncogenic KRAS variants, with intended applications across KRAS-mutated solid tumors such as pancreatic, colorectal, and some lung cancers. Based on the provided context, the program was preclinical/IND-enabling and appears not to have advanced clinically before SQZ's asset sale and dissolution.

Targets

pMHC-I (Peptide–MHC class I complex)

Beyond the preview

Go deeper on SQZ-APC-KRAS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SQZ-APC-KRAS.

Explore the full profile